Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects
Open Access
- 15 June 2026
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0052426
Abstract
Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa . This study evaluated the intrapulmonary pharmacokinetics of funobactam, imipenem, and cilastatin in healthy subjects. Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses. Bronchoalveolar lavage (BAL) was performed at 1, 2, 4, or 6 h after the fifth dose ( n = 5 per sampling time point) to determine epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations. The means from each plasma sampling time corresponding to the BAL sampling time were used to estimate the area under the curve from 0 to 6 h (AUC 0–6h ) for plasma, and mean concentrations from BAL sampling times from each cohort were used to estimate AUC 0–6h for ELF and AM concentrations. Intrapulmonary penetration was assessed using AUC 0–6h ratios of ELF and AM to unbound plasma. The AUC 0–6h ratios of ELF to unbound plasma for funobactam, imipenem, and cilastatin were 35.2%, 31.8%, and 23.0%, respectively, and the AUC 0–6h ratios of AM to unbound plasma were 36.6%, 16.8%, and 17.9%, respectively. Funobactam penetrated ELF and AM and exhibited higher intrapulmonary penetration than imipenem and cilastatin, supporting the clinical evaluation of funobactam in combination with imipenem for the treatment of nosocomial pneumonia. This study is registered with ClinicalTrials.gov as NCT04802863 .Keywords
Funding Information
- Evopoint Biosciences USA, Inc (Pulmonary Penetration Study)
This publication has 24 references indexed in Scilit:
- A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative BacteriaInternational Journal of Antimicrobial Agents, 2024
- Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killingJournal of Antimicrobial Chemotherapy, 2023
- In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from ChinaJournal of Global Antimicrobial Resistance, 2022
- Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An UpdateClinical Pharmacokinetics, 2021
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial InfectionsClinical Infectious Diseases, 2019
- β-Lactamases and β-Lactamase Inhibitors in the 21st CenturyJournal of Molecular Biology, 2019
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial InfectionsDrugs, 2018
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lungCurrent Opinion in Pharmacology, 2017
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012